Abstract:Increased proliferation and survival of resident cells in small pulmonary arteries (PA) are important drivers of pulmonary hypertension (PH). Tuberous sclerosis complex 2 (TSC2) is a negative regulator of mTOR complex 1 and cell growth. Here we show that TSC2 is deficient in small remodeled PA/PA vascular smooth muscle cells (PAVSMC) from human PAH and experimental PH lungs. TSC2 deficiency was reproduced in vitro by maintaining PAVSMC on pathologically stiff substrates and was required for stiffness-induced proliferation, accumulation of transcriptional co-activators YAP/TAZ and up-regulation of mTOR. Depletion of TSC2 reproduced PH features in vitro in human PAVSMC and in vivo in SM22-Tsc2+/− mice. TSC2 loss in PAVSMC was supported by YAP and led to the up-regulation of YAP/TAZ and mTOR via modulating the extracellular matrix (ECM) composition. ECM, produced by TSC2-deficient PAVSMC, promoted growth of non-diseased PA adventitial fibroblasts and PAVSMC, which, in turn, was prevented by α5β1 integrin receptor antagonist ATN161. In vitro , molecular and pharmacological (SRT2104) restoration of TSC2 down-regulated YAP/TAZ, mTOR, and ECM production, inhibited proliferation and induced apoptosis in human PAH PAVSMC. In vivo , orally administrated SRT2104 restored TSC2, resolved pulmonary vascular remodeling, PH, and improved right heart in two rodent models of PH. Thus, PAVSMC TSC2 is a critical integrator of ECM composition and stiffness with pro-proliferative signaling and PH, and the restoration of functional TSC2 could be an attractive therapeutic option to treat PH. One Sentence Summary TSC2 acts as mechanosensor and mechanotransducer, integrating ECM composition and stiffness with pro-proliferative signaling in pulmonary vasculature; its deficiency in PA vascular smooth muscle cells results in ECM remodeling, hyper-proliferation and pulmonary hypertension, which could be reversed by pharmacological restoration of functional TSC2. ### Competing Interest Statement The authors have declared no competing interest. * BrdU : Bromodeoxyuridine BSA : Bovine serum albumin Col1A1 : Collagen 1A1 DAPI : 4’,6-diamidino-2-phenylindole ECM : Extracellular matrix ET-1 : Endotelin-1 FN : Fibronectin GFP : Green fluorescent protein H&E : Hematoxylin and eosin IGF-1 : Insulin growth factor 1 IL-6 : Interleukin-6 IPAH : Idiopathic pulmonary arterial hypertension LAM : Lymphangioleiomyomatosis LV : Left ventricular/ventricle MAP : Mean arterial pressure mTOR : Mechanistic target of rapamycin mTORC : Mechanistic target of rapamycin complex PA : Pulmonary artery PA MT : Pulmonary artery medial thickness PAAF : Pulmonary artery adventitial fibroblast PAEC : Pulmonary artery endothelial cell PAH : Pulmonary arterial hypertension PAP : PA pressure PAVSMC : Pulmonary artery vascular smooth muscle cells PDGF-BB : Platelet-derived growth factor-BB PH : Pulmonary hypertension RV : Right ventricular/ventricle SIRT1 : Sirtuin 1 sLVP : Systolic left ventricular pressure SM22 : Smooth muscle protein 22-alpha SMA : Smooth muscle a-actin sRVP : Systolic right ventricular pressure SuHx : SU5416/Hypoxia TNF-α : Tumor necrosis factor-a TSC2 : Tuberous sclerosis complex 2 TUNEL : Terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling WT : Wild type YAP : Yes-associated protein

A Potential Role for Exosomal Translationally Controlled Tumor Protein Export in Vascular Remodeling in Pulmonary Arterial Hypertension.

Endothelial Progenitor Cells May Inhibit Apoptosis of Pulmonary Microvascular Endothelial Cells: New Insights into Cell Therapy for Pulmonary Arterial Hypertension

Paracrine Effects Of Bone Marrow-Derived Endothelial Progenitor Cells: Cyclooxygenase-2/Prostacyclin Pathway In Pulmonary Arterial Hypertension

Endothelial Progenitor Cell-Based Therapy for Pulmonary Arterial Hypertension

Interruption of CD40 Pathway Improves Efficacy of Transplanted Endothelial Progenitor Cells in Monocrotaline Induced Pulmonary Arterial Hypertension.

PTPN1 Deficiency Modulates BMPR2 Signaling and Induces Endothelial Dysfunction in Pulmonary Arterial Hypertension

Abstract 18497: Attenuated Endothelial Cd39 Activity Mediates Vascular Remodeling in Pulmonary Arterial Hypertension

TSC2-extracellular matrix crosstalk controls pulmonary vascular proliferation and pulmonary hypertension

Molecular Characterization and Elucidation of Pathways to Identify Novel Therapeutic Targets in Pulmonary Arterial Hypertension

Transcriptomic profiling highlights cell proliferation in the progression of experimental pulmonary hypertension in rats

Cross-talk between TSC2 and the extracellular matrix controls pulmonary vascular proliferation and pulmonary hypertension

Modulation of EPC: A New Hope for Pulmonary Artery Hypertension Treatment

Characteristic disease defects in circulating endothelial cells isolated from patients with pulmonary arterial hypertension

Bone morphogenetic protein signalling in pulmonary arterial hypertension: revisiting the BMPRII connection

Abstract 12497: Diminished Cavolin-1 Expression and Augmented Nitrative Stress Secondary to Prolyl-4 Hydroxylase 2 Deficiency Contribute to Obliterative Vascular Remodeling and Severe Pulmonary Arterial Hypertension

Abstract 10845: Akt-Dependent Vacuolar Protein Sorting 34 Activation Promotes Pulmonary Vascular Smooth Muscle Cell Proliferation and Survival in Pulmonary Hypertension

Abstract 15826: SCUBE1 Controls BMPR2-relevant Pulmonary Endothelial Function: Implications for Diagnostic Marker Development in Pulmonary Arterial Hypertension

Targeting translational read-through of premature termination mutations in <i>BMPR2</i> with PTC124 for pulmonary arterial hypertension

Exploring the Endothelin-1 pathway in chronic thromboembolic pulmonary hypertension microvasculopathy

Expression of Mutant BMPR-II in Pulmonary Endothelial Cells Promotes Apoptosis and a Release of Factors That Stimulate Proliferation of Pulmonary Arterial Smooth Muscle Cells

Overexpressed pigment epithelium-derived factor alleviates pulmonary hypertension in two rat models induced by monocrotaline and SU5416/hypoxia